Trial Profile
A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2023
Price :
$35
*
At a glance
- Drugs Flecainide (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Therapeutic Use
- Acronyms INSTANT
- Sponsors InCarda Therapeutics
- 02 Dec 2022 Status changed from active, no longer recruiting to completed.
- 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 13 Jan 2022 Status changed from recruiting to active, no longer recruiting.